A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia.

@article{Willmore2004AND,
  title={A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia.},
  author={Elaine Willmore and Sarah de Caux and Nicola J. Sunter and Michael John Tilby and Graham Hunter Jackson and Caroline Ann Austin and Barbara W. Durkacz},
  journal={Blood},
  year={2004},
  volume={103 12},
  pages={4659-65}
}
We report for the first time the use of a selective small-molecule inhibitor of DNA repair to potentiate topoisomerase II (topo II) poisons, identifying DNA-dependent protein kinase (DNA-PK) as a potential target for leukemia therapy. Topo II poisons form cleavable complexes that are processed to DNA double-strand breaks (DSBs). DNA-PK mediates nonhomologous end joining (NHEJ). Inhibition of this DSB repair pathway may sensitize cells to topo II poisons. We investigated the effects of a novel… CONTINUE READING
Highly Influential
This paper has highly influenced 12 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
95 Extracted Citations
47 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 95 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 47 references

Acute myelogenous leukemia

  • MA Lichtman, JL Liesveld
  • 2002

Similar Papers

Loading similar papers…